Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Effectiveness of pertussis vaccination in pregnancy to prevent hospitalisation in infants aged <2 months and effectiveness of both primary vaccination and mother's vaccination in pregnancy in infants aged 2-11 months

L. Merdrignac, L. Acosta, A. Habington, M. Garcìa Cenoz, E. Pandolfi, K. Fabiánová, I. Jordan, N. O'Sullivan, A. Navasués, AE. Tozzi, J. Zavadilová, M. Jané, S. Cotter, NI. Pitillas, C. Rizzo, P. Křížová, T. Hanslik, C. Muñoz Almagro, L. Pastore,...

. 2022 ; 40 (44) : 6374-6382. [pub] 20220929

Language English Country Netherlands

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22033031
E-resources Online Full text

NLK ProQuest Central from 2002-01-01 to 2 months ago
Nursing & Allied Health Database (ProQuest) from 2002-01-01 to 2 months ago
Health & Medicine (ProQuest) from 2002-01-01 to 2 months ago
Family Health Database (ProQuest) from 2002-01-01 to 2 months ago
Health Management Database (ProQuest) from 2002-01-01 to 2 months ago
Public Health Database (ProQuest) from 2002-01-01 to 2 months ago

Links

PubMed 36182617
DOI 10.1016/j.vaccine.2022.09.054
Knihovny.cz E-resources

BACKGROUND: PERTINENT is an active hospital-based surveillance system for pertussis in infants. In 2019, four of the six participating European countries recommended pertussis vaccination in pregnancy. Among infants aged <2 months, we measured the vaccine effectiveness (VE) in pregnancy; among infants aged 2-11 months, VE of vaccination in pregnancy and of primary vaccination (PV). METHODS: From December 2015 to 2019, we included all infants aged <1 year presenting with pertussis-like symptoms. Using a test-negative-design, cases were infants testing positive for Bordetella pertussis by PCR or culture. Controls were those testing negative for all Bordetella species. Vaccinated mothers were those who received vaccine in pregnancy. Vaccinated infants were those who received ≥1 dose of PV > 14 days before symptom onset. We excluded infants with unknown maternal or PV status or with mothers vaccinated ≤14 days before delivery. We calculated pooled VE as 100 * (1-odds ratio of vaccination) adjusted for study site, onset date in quarters and infants' age group. RESULTS: Of 829 infants presenting with pertussis-like symptoms, 336 (41%) were too young for PV. For the VE in pregnancy analysis, we included 75 cases and 201 controls. Vaccination in pregnancy was recorded for 9 cases (12%) and 92 controls (46%), adjusted VE was between 75% [95%CI: 35-91%] and 88% [95%CI: 57-96%]. Of 493 infants eligible for PV, we included 123 cases and 253 controls. Thirty-one cases and 98 controls recorded both PV with ≥ 1 dose and vaccination in pregnancy, adjusted VE was between 74% [95%CI: 33-90] and 95% [95%CI: 69-99]; 27 cases and 53 controls recorded PV only, adjusted VE was between 68% [95%CI: 27-86] and 94% [95%CI: 59-99]. CONCLUSION: Our findings suggest that vaccination in pregnancy reduces pertussis incidence in infants too young for PV. In infants aged 2-11 months, PV only and both PV and vaccination in pregnancy provide significant protection against severe pertussis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22033031
003      
CZ-PrNML
005      
20230131151501.0
007      
ta
008      
230120s2022 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.vaccine.2022.09.054 $2 doi
035    __
$a (PubMed)36182617
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Merdrignac, Lore $u Epidemiology Department, Epiconcept, Paris, France. Electronic address: l.merdrignac@epiconcept.fr
245    10
$a Effectiveness of pertussis vaccination in pregnancy to prevent hospitalisation in infants aged <2 months and effectiveness of both primary vaccination and mother's vaccination in pregnancy in infants aged 2-11 months / $c L. Merdrignac, L. Acosta, A. Habington, M. Garcìa Cenoz, E. Pandolfi, K. Fabiánová, I. Jordan, N. O'Sullivan, A. Navasués, AE. Tozzi, J. Zavadilová, M. Jané, S. Cotter, NI. Pitillas, C. Rizzo, P. Křížová, T. Hanslik, C. Muñoz Almagro, L. Pastore, S. Bacci, A. Moren, M. Valenciano, PERTINENT Group
520    9_
$a BACKGROUND: PERTINENT is an active hospital-based surveillance system for pertussis in infants. In 2019, four of the six participating European countries recommended pertussis vaccination in pregnancy. Among infants aged <2 months, we measured the vaccine effectiveness (VE) in pregnancy; among infants aged 2-11 months, VE of vaccination in pregnancy and of primary vaccination (PV). METHODS: From December 2015 to 2019, we included all infants aged <1 year presenting with pertussis-like symptoms. Using a test-negative-design, cases were infants testing positive for Bordetella pertussis by PCR or culture. Controls were those testing negative for all Bordetella species. Vaccinated mothers were those who received vaccine in pregnancy. Vaccinated infants were those who received ≥1 dose of PV > 14 days before symptom onset. We excluded infants with unknown maternal or PV status or with mothers vaccinated ≤14 days before delivery. We calculated pooled VE as 100 * (1-odds ratio of vaccination) adjusted for study site, onset date in quarters and infants' age group. RESULTS: Of 829 infants presenting with pertussis-like symptoms, 336 (41%) were too young for PV. For the VE in pregnancy analysis, we included 75 cases and 201 controls. Vaccination in pregnancy was recorded for 9 cases (12%) and 92 controls (46%), adjusted VE was between 75% [95%CI: 35-91%] and 88% [95%CI: 57-96%]. Of 493 infants eligible for PV, we included 123 cases and 253 controls. Thirty-one cases and 98 controls recorded both PV with ≥ 1 dose and vaccination in pregnancy, adjusted VE was between 74% [95%CI: 33-90] and 95% [95%CI: 69-99]; 27 cases and 53 controls recorded PV only, adjusted VE was between 68% [95%CI: 27-86] and 94% [95%CI: 59-99]. CONCLUSION: Our findings suggest that vaccination in pregnancy reduces pertussis incidence in infants too young for PV. In infants aged 2-11 months, PV only and both PV and vaccination in pregnancy provide significant protection against severe pertussis.
650    _2
$a těhotenství $7 D011247
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a pertuse $x epidemiologie $7 D014917
650    _2
$a matky $7 D009035
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a pertusová vakcína $7 D010567
650    _2
$a vakcinace $7 D014611
650    _2
$a hospitalizace $7 D006760
655    _2
$a časopisecké články $7 D016428
700    1_
$a Acosta, Lesly $u Public Health Agency of Catalonia (ASPCAT), Barcelona, Spain; Universitat Politècnica de Catalunya- BarcelonaTech (UPC), Barcelona, Spain
700    1_
$a Habington, Adele $u Children's Health Ireland, Crumlin, Dublin, Ireland
700    1_
$a Garcìa Cenoz, Manuel $u Instituto de Salud Pública de Navarra, IdiSNA - Navarre Institute for Health Research, Pamplona, Spain
700    1_
$a Pandolfi, Elisabetta $u Multifactorial Disease and Complex Phenotype Research Area, Bambino Gesù Children Hospital, Rome, Italy
700    1_
$a Fabiánová, Kateřina $u National Institute of Public Health, Prague, Czech Republic
700    1_
$a Jordan, Iolanda $u Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Barcelona, Spain; University of Barcelona, Barcelona, Spain
700    1_
$a O'Sullivan, Niam $u Children's Health Ireland, Crumlin, Dublin, Ireland
700    1_
$a Navasués, Ana $u Instituto de Salud Pública de Navarra, IdiSNA - Navarre Institute for Health Research, Pamplona, Spain
700    1_
$a Tozzi, Alberto E $u Multifactorial Disease and Complex Phenotype Research Area, Bambino Gesù Children Hospital, Rome, Italy
700    1_
$a Zavadilová, Jana $u National Institute of Public Health, Prague, Czech Republic
700    1_
$a Jané, Mireia $u Public Health Agency of Catalonia (ASPCAT), Barcelona, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Barcelona, Spain; University of Barcelona, Barcelona, Spain
700    1_
$a Cotter, Suzanne $u Health Protection Surveillance Centre, Dublin, Ireland
700    1_
$a Pitillas, Nerea I $u Instituto de Salud Pública de Navarra, IdiSNA - Navarre Institute for Health Research, Pamplona, Spain
700    1_
$a Rizzo, Caterina $u Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
700    1_
$a Křížová, Pavla $u National Institute of Public Health, Prague, Czech Republic
700    1_
$a Hanslik, Thomas $u Sorbonne University, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
700    1_
$a Muñoz Almagro, Carmen $u Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Barcelona, Spain; Medicine Department, Universitat Internacional de Catalunya, Barcelona, Spain
700    1_
$a Pastore, Lucia $u European Centre for Diseases Control and Prevention, Stockholm, Sweden
700    1_
$a Bacci, Sabrina $u European Centre for Diseases Control and Prevention, Stockholm, Sweden
700    1_
$a Moren, Alain $u Epidemiology Department, Epiconcept, Paris, France
700    1_
$a Valenciano, Marta $u Epidemiology Department, Epiconcept, Paris, France
710    2_
$a PERTINENT Group
773    0_
$w MED00004631 $t Vaccine $x 1873-2518 $g Roč. 40, č. 44 (2022), s. 6374-6382
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36182617 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151457 $b ABA008
999    __
$a ok $b bmc $g 1891665 $s 1184366
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 40 $c 44 $d 6374-6382 $e 20220929 $i 1873-2518 $m Vaccine $n Vaccine $x MED00004631
LZP    __
$a Pubmed-20230120
Back

Find record

Citation metrics

Archiving options